These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 30614754)

  • 1. The use of cell-mediated immunity for the evaluation of influenza vaccines: an upcoming necessity.
    Gianchecchi E; Torelli A; Montomoli E
    Hum Vaccin Immunother; 2019; 15(5):1021-1030. PubMed ID: 30614754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
    Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
    mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial.
    van Doorn E; Pleguezuelos O; Liu H; Fernandez A; Bannister R; Stoloff G; Oftung F; Norley S; Huckriede A; Frijlink HW; Hak E
    BMC Infect Dis; 2017 Apr; 17(1):241. PubMed ID: 28376743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influenza immunology evaluation and correlates of protection: a focus on vaccines.
    Trombetta CM; Montomoli E
    Expert Rev Vaccines; 2016 Aug; 15(8):967-76. PubMed ID: 26954563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The establishment of surrogates and correlates of protection: Useful tools for the licensure of effective influenza vaccines?
    Ward BJ; Pillet S; Charland N; Trepanier S; Couillard J; Landry N
    Hum Vaccin Immunother; 2018 Mar; 14(3):647-656. PubMed ID: 29252098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, immunogenicity and infectivity of new live attenuated influenza vaccines.
    Isakova-Sivak I; Rudenko L
    Expert Rev Vaccines; 2015; 14(10):1313-29. PubMed ID: 26289975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological assessment of influenza vaccines and immune correlates of protection.
    Reber A; Katz J
    Expert Rev Vaccines; 2013 May; 12(5):519-36. PubMed ID: 23659300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of Influenza Vaccines: Evidence for Differential Effect of Secondary Vaccination on Humoral and Cellular Immunity.
    Rosendahl Huber SK; Hendriks M; Jacobi RHJ; van de Kassteele J; Mandersloot-Oskam JC; van Boxtel RAJ; Wensing AMJ; Rots NY; Luytjes W; van Beek J
    Front Immunol; 2018; 9():3103. PubMed ID: 30761157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model.
    Memoli MJ; Shaw PA; Han A; Czajkowski L; Reed S; Athota R; Bristol T; Fargis S; Risos K; Powers JH; Davey RT; Taubenberger JK
    mBio; 2016 Apr; 7(2):e00417-16. PubMed ID: 27094330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influenza vaccines: T-cell responses deserve more attention.
    Schotsaert M; Saelens X; Leroux-Roels G
    Expert Rev Vaccines; 2012 Aug; 11(8):949-62. PubMed ID: 23002976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults.
    Della Cioppa G; Nicolay U; Lindert K; Leroux-Roels G; Clement F; Castellino F; Galli G; Groth N; Del Giudice G
    Hum Vaccin Immunother; 2012 Feb; 8(2):216-27. PubMed ID: 22426371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between the frequency of influenza vaccination and cell-mediated immunity.
    Otani N; Shima M; Ueda T; Ichiki K; Nakajima K; Takesue Y; Honjo K; Yoshida N; Kawata S; Okuno T
    J Immunol Methods; 2018 Jul; 458():58-62. PubMed ID: 29684427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.
    Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC
    mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors affecting immune responses to the influenza vaccine.
    Castrucci MR
    Hum Vaccin Immunother; 2018 Mar; 14(3):637-646. PubMed ID: 28617077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Registration of influenza vaccines for children in Europe.
    Granström M; Voordouw AC
    Vaccine; 2011 Oct; 29(43):7572-5. PubMed ID: 21820474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review and meta-analysis of cross-reactivity of antibodies induced by oil-in-water emulsion adjuvanted influenza H5N1 virus monovalent vaccines.
    Chada KE; Forshee R; Golding H; Anderson S; Yang H
    Vaccine; 2017 May; 35(24):3162-3170. PubMed ID: 28483200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlates of vaccine protection from influenza and its complications.
    McCullers JA; Huber VC
    Hum Vaccin Immunother; 2012 Jan; 8(1):34-44. PubMed ID: 22252001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
    Vesikari T; Forstén A; Herbinger KH; Cioppa GD; Beygo J; Borkowski A; Groth N; Bennati M; von Sonnenburg F
    Vaccine; 2012 Feb; 30(7):1388-96. PubMed ID: 22192847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Licensing the first reduced, 6 µg dose whole virion, aluminum adjuvanted seasonal influenza vaccine - A randomized-controlled multicenter trial.
    Vajo Z; Kalabay L; Vajo P; Balaton G; Rozsa N; Torzsa P
    Vaccine; 2019 Jan; 37(2):258-264. PubMed ID: 30497837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
    Walz L; Kays SK; Zimmer G; von Messling V
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29925654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.